# Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies

> **NCT01818479** · PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 10 (actual)

## Conditions studied

- High Risk Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** stem cell transplant
- **PROCEDURE:** Stem cell transplant

## Key facts

- **NCT ID:** NCT01818479
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-12
- **Primary completion:** 2019-04-01
- **Final completion:** 2019-04-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Trial discontinued prior to starting Phase II portion due to low accrual.
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818479, "Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01818479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*